Nucleic acids, drug compositions and complexes, as well as methods for their preparation and use.

Modified siRNAs and drug compositions targeting kininogen gene expression in the liver provide a solution to suppress sepsis progression by effectively inhibiting KNG gene expression, addressing the need for effective sepsis treatment.

JP7872622B2Active Publication Date: 2026-06-10SUZHOU RIBO LIFE SCIENCE CO LTD
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SUZHOU RIBO LIFE SCIENCE CO LTD
Filing Date
2024-12-16
Publication Date
2026-06-10

AI Technical Summary

⚠Technical Problem

Current treatments for sepsis, a systemic inflammatory response syndrome caused by infection, lack effective methods to suppress kininogen gene expression, which is crucial for mitigating the progression of the disease.

⚗Method used

Development of siRNAs and drug compositions that specifically target and suppress kininogen gene expression in the liver, utilizing modified siRNAs and delivery systems to inhibit KNG gene expression through RNA interference.

🎯Benefits of technology

The siRNAs and drug compositions effectively suppress KNG gene expression, achieving high stability and target mRNA repression, reducing sepsis symptoms and progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

To provide an siRNA and a pharmaceutical composition which inhibit kininogen (KNG) expression and thus can achieve the purpose of effectively inhibiting a life span of a pathogen so as to alleviate the progress of the septicemia and reverse the pathology.SOLUTION: The siRNA contains a sense strand and an antisense strand. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. Lengths of the sense strand and the antisense strand are the same or different, the length of the sense strand is 19-23 nucleotides, and the length of the antisense strand is 19-26 nucleotides. The sense strand contains a specific nucleotide sequence I. The antisense strand contains a specific nucleotide sequence II. The nucleotide sequence I and the nucleotide sequence II form a substantially reverse complementary or completely reverse complementary double-stranded region. The siRNA inhibits expression of a kininogen gene in hepatocytes.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art